<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02036359</url>
  </required_header>
  <id_info>
    <org_study_id>201203009MIB</org_study_id>
    <nct_id>NCT02036359</nct_id>
  </id_info>
  <brief_title>Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca</brief_title>
  <acronym>Oncology</acronym>
  <official_title>An Open-label, Randomized, Phase II Study of Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of Stage IIIA Lung Adenocarcinoma With Epidermal Growth Factor Receptor Gene Mutation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare clinical response (complete response and partial response) by RECIST) rates by&#xD;
      RECIST between erlotinib monotherapy and docetaxel plus cisplatin chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      an open-label, multi-centre, randomized, phase II study evaluating efficacy of erlotinib&#xD;
      monotherapy vs. docetaxel plus cisplatin chemotherapy.&#xD;
&#xD;
      Patients with histological documented stage IIIA lung adenocarcinoma. The tumor specimens&#xD;
      were examined for EGFR gene mutation (Exon 18-21).&#xD;
&#xD;
      Those with exon 19 deletion and L858R, G719X, L861Q mutation were randomized as erlotinib&#xD;
      monotherapy or docetaxel plus cisplatin chemotherapy.&#xD;
&#xD;
      The randomization will be stratified by center&#xD;
&#xD;
      Study treatment Patients will receive treatment for 9 weeks unless disease progression,&#xD;
      unacceptable toxicity or death.&#xD;
&#xD;
      Erlotinib arm:&#xD;
&#xD;
      Patients in erlotinib arm will take erlotinib 150mg/day for 9 weeks unless disease&#xD;
      progression, unacceptable toxicity or death.&#xD;
&#xD;
      Chemotherapy arm:&#xD;
&#xD;
      Patients in chemotherapy arm will then receive 3 cycles (9 weeks) of chemotherapy with&#xD;
      docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.&#xD;
&#xD;
      Treatment failure will include patients who fail to complete 3 cycles (9 weeks) of study&#xD;
      treatments due to disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients with no disease progression after terminating study treatment will undergo surgical&#xD;
      resection and be followed until disease progression is noted, or study end. Survival will be&#xD;
      recorded and analyzed.&#xD;
&#xD;
      If progressive disease or unacceptable toxicity occurs during study treatments, patients will&#xD;
      be treated at discretion of investigator according to local protocol.&#xD;
&#xD;
      Please note:&#xD;
&#xD;
      • If it is judged by the investigator to be in the best interest of the patient, patients&#xD;
      discontinuing study treatment may receive second-line treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Event</measure>
    <time_frame>Within 28 days of last study dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Non-small Cell Lung Cancer(NSCLC)</condition>
  <arm_group>
    <arm_group_label>erlotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in erlotinib arm will take erlotinib 150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in chemotherapy arm will then receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.&#xD;
Treatment failure will include patients who fail to complete 3 cycles (9 weeks) of study treatments due to disease progression or unacceptable toxicity.&#xD;
Patients with no disease progression after terminating study treatment will undergo surgical resection and be followed until disease progression is noted, or study end. Survival will be recorded and analyzed.&#xD;
If progressive disease or unacceptable toxicity occurs during study treatments, patients will be treated at discretion of investigator according to local protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.</description>
    <arm_group_label>erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Age ≥ 18 years, male or female&#xD;
&#xD;
               -  Able to comply with the protocol&#xD;
&#xD;
               -  Histologically documented stage IIIA lung adenocarcinoma&#xD;
&#xD;
               -  ECOG performance status 0-2&#xD;
&#xD;
               -  If the patient has the use coumarin (coumarin) (also to be called coumadin or&#xD;
                  warfarin), the patient applies drugs previous 7 days at the experiment to stop&#xD;
                  the medicine, and changes to other for to use the medicine.&#xD;
&#xD;
               -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
               -  Tumor specimen with EGFR gene mutation of exon 19 deletion and L858R, G719X,&#xD;
                  L861Q mutation&#xD;
&#xD;
               -  Adequate hematological function: ANC ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L, Hb ≥&#xD;
                  9 g/dL&#xD;
&#xD;
               -  Data of INR and PTT should be available in patients taking anticoagulants&#xD;
                  concomitantly, with INR ≤ 1.5 and PTT ≤ 1.5 times the upper limit of normal (x&#xD;
                  ULN ) within 7 days prior to starting study treatment&#xD;
&#xD;
               -  Adequate liver function: serum bilirubin ≤ 1.5 x ULN; transaminases ≤ 2.5 x ULN&#xD;
&#xD;
               -  Adequate renal function: 24-hour urine creatinine clearance or creatinine&#xD;
                  clearance measured and calculated according to the formula of Cockroft and Gault&#xD;
                  ≥ 60ml/min&#xD;
&#xD;
               -  Negative serum pregnancy test within 7 days of starting study treatment in&#xD;
                  pre-menopausal women&#xD;
&#xD;
               -  Written informed consent.&#xD;
&#xD;
               -  Patients are willing to complete FACT-L, ED-5Q, or pharmacoeconomic&#xD;
                  questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Prior chemotherapy or treatment with another systemic anti-cancer agent (for example&#xD;
             monoclonal antibody, tyrosine kinase inhibitor)&#xD;
&#xD;
               -  Mixed adenocarcinoma and other histological type of lung cancer&#xD;
&#xD;
               -  Unable to take oral medicine&#xD;
&#xD;
               -  Pregnant or lactating women&#xD;
&#xD;
               -  Fertile men or women of childbearing potential not using adequate contraception&#xD;
                  (oral contraceptives, intrauterine device or barrier method of contraception in&#xD;
                  conjunction with spermicidal jelly or surgically sterile)&#xD;
&#xD;
               -  Malignancies other than NSCLC within 5 years prior to randomization, except for&#xD;
                  adequately treated carcinoma in situ of the cervix, basal or squamous cell skin&#xD;
                  cancer, localized prostate cancer treated surgically with curative intent, DCIS&#xD;
                  treated surgically with curative intent&#xD;
&#xD;
               -  Treatment with any other investigational agent, or participation in another&#xD;
                  clinical trial within 30 days prior to starting study treatment&#xD;
&#xD;
               -  Known hypersensitivity to any of the study drugs&#xD;
&#xD;
               -  Concurrent cancer treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chong-Jen Yu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chong Jen YU, M.D., Ph.D</last_name>
    <email>jefferycjyu@ntu.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chiung Hui Huang</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>67779</phone_ext>
    <email>qoojoan@yahoo.com.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Oncology, National Taiwan University Hospital</name>
      <address>
        <city>Taipei,</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chong Jen YU, M.D., Ph.D.</last_name>
      <email>jefferycjyu@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>January 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2014</study_first_posted>
  <last_update_submitted>January 14, 2014</last_update_submitted>
  <last_update_submitted_qc>January 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer(NSCLC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

